QURE
Overvalued by 110.6% based on the discounted cash flow analysis.
Market cap | $3.01 Billion |
---|---|
Enterprise Value | $2.83 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $-4.92 |
Beta | 0.56 |
Outstanding Shares | 54,807,967 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -15.13 |
---|---|
PEG | 45.83 |
Price to Sales | - |
Price to Book Ratio | -54.92 |
Enterprise Value to Revenue | 197.5 |
Enterprise Value to EBIT | -15.39 |
Enterprise Value to Net Income | -15 |
Total Debt to Enterprise | 0.03 |
Debt to Equity | -18.05 |
No data
No data
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...